Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Clenafin Authorized Generic Hits Japan Market: Kaken
September 16, 2025
- Lilly Confirms Safety of Oral GLP-1 Orforglipron in Japan PIII
September 16, 2025
- Pfizer’s Ulcerative Colitis Drug Velsipity Now Available in Japan
September 16, 2025
- Predictability Key to Novartis’ Japan Investment, Says International Chief
September 16, 2025
- Eisai Sees “Best-in-Class” Promise for E2086 as Once-Daily Narcolepsy Drug
September 12, 2025
- LEO Pharma Reinforces Japan Push toward Dermatology Leadership
September 12, 2025
- Enhertu’s Tumor-Agnostic Use Now under EU Review: Daiichi Sankyo
September 12, 2025
- Sawai, Nichi-Iko to Consolidate 15 APIs as Sector Tackles Small-Lot Production
September 11, 2025
- Sawai and T’s Pharma Won Forxiga Generics by Skirting Patent, Will the Strategy Hold?
September 11, 2025
- Welireg Expected to Preserve Organ Function in VHL Disease: Urologist
September 11, 2025
- Sobi Japan Targets Five Rare Diseases in Five Years, Says President
September 10, 2025
- Teijin Pharma Bets on Ascendis Rare Disease Assets as Feburic Sales Crumble
September 10, 2025
- Gilead Says It Has No Intention to Scrap License Deal: Carna Bio
September 10, 2025
- Teikoku to Take Over Janssen’s Lopemin in Japan
September 10, 2025
- Nippon Shinyaku’s EGPA Drug Bags Fast-Track Status in US
September 10, 2025
- Lilly Japan Ramps Up Seishin Plant with New Building and Packaging Line
September 9, 2025
- Janssen Files TAR-200 in Japan for High-Risk Bladder Cancer
September 9, 2025
- Amicus CEO Confident on US$1 Billion Sales Target as Japan Pompe Launch Gets Underway
September 9, 2025
- GSK Recalls 7 Lots of Omjjara in Japan over Quality Issue
September 9, 2025
- Takeda Nabs Label Expansion for VWD Drug Vonvendi in US
September 9, 2025
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…